MSB 3.16% $1.31 mesoblast limited

Ann: COVID ARDS Trial Topline 60-Day Results, page-1582

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 470 Posts.
    lightbulb Created with Sketch. 898
    In the Aus biz interview, Silviu suggests that the “large” Novartis partnership deal shall be closed soon. The OTAT meeting shall clear the way for the approval of potency assays which shall be integral to the phase 3 trial which is already designed.
    So to recap, the COVID ARDS phase 3 trial shall be confirmed immediately or soon after Novartis partnership deal is closed.
    If we have a properly designed confirmatory trial, I would put the chances of an early stop due to efficacy being more than 50% chance. An EUA is within sight and there might be more color shortly on the design of the trial and interim analysis points.

    Last edited by aquazul: 28/11/21
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.